TerminatedPhase 2NCT00215540

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Studying Bronchopulmonary dysplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Windtree Therapeutics
Principal Investigator
Carlos Guardia, MD, MD
Windtree Therapeutics
Intervention
Lucinactant 175 mg/kg(drug)
Enrollment
136 enrolled
Eligibility
All sexes
Timeline
20052006

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00215540 on ClinicalTrials.gov

Other trials for Bronchopulmonary dysplasia

Additional recruiting or active studies for the same condition.

See all trials for Bronchopulmonary dysplasia

← Back to all trials